Buy Actoplus met

Actoplus met

Actoplus Met: Diabetes Medication Overview

Actoplus Met is a prescription pill that combines two active ingredients-metformin and pioglitazone. It belongs to the antidiabetic drug class and is marketed in Hong Kong under the supervision of the Department of Health’s Drug Office. The combination is formulated as 500 mg metformin hydrochloride and 15 mg pioglitazone hydrochloride per tablet.

How Actoplus Met Works in the Body

Metformin primarily reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, especially skeletal muscle. It does this by activating the enzyme AMP-activated protein kinase (AMPK), which helps shift cellular metabolism toward glucose utilization and away from glucose synthesis.

Pioglitazone belongs to the thiazolidinedione (TZD) family. It activates the peroxisome proliferator-activated receptor-γ (PPAR-γ), a nuclear receptor that regulates genes involved in glucose and lipid metabolism. Activation of PPAR-γ increases insulin-dependent glucose uptake and reduces circulating free fatty acids, further enhancing insulin sensitivity.

Together, the two agents address insulin resistance from complementary pathways, producing a greater overall reduction in fasting plasma glucose and glycated hemoglobin (HbA1c) than either component alone.

Conditions Treated by Actoplus Met

Actoplus Met is approved in Hong Kong for the treatment of type 2 diabetes mellitus when diet, exercise, and monotherapy with either metformin or pioglitazone do not achieve adequate glycaemic control. It is intended for adult patients who require an additional glucose-lowering effect and can tolerate both components of the combination.

Patient Suitability and Contraindications

Who Should Use Actoplus Met?

• Adults with type 2 diabetes whose target HbA1c cannot be reached with lifestyle measures and a single antidiabetic agent.
• Patients with documented insulin resistance who can benefit from enhanced peripheral insulin sensitivity.

Absolute Contraindications

• Known hypersensitivity to metformin, pioglitazone, or any excipients in the tablet.
• Severe renal impairment (eGFR < 30 mL/min/1.73 m²) because of the risk of lactic acidosis with metformin.
• History of lactic acidosis.
• Unstable or acute heart failure (NYHA class III or IV) due to the edema-promoting effect of pioglitazone.
• Active hepatic disease or hepatic impairment that could affect drug metabolism.
• Pregnancy and lactation (both components are contraindicated).

Relative Contraindications

• Moderate renal impairment (eGFR 30-45 mL/min/1.73 m²): dose adjustment and close monitoring are required.
• Elderly patients: increased sensitivity to both metformin and pioglitazone; start at the lowest dose and titrate cautiously.
• History of bladder cancer: pioglitazone has been associated with a possible increased risk; use only if benefits outweigh risks.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Gastrointestinal upset (nausea, abdominal discomfort, diarrhoea) - often transient and linked to metformin.
• Weight gain or mild fluid retention - more common with pioglitazone.
• Metallic taste - occasional with metformin.

Serious Adverse Events

• Lactic acidosis (rare but life-threatening) - characterized by rapid breathing, abdominal pain, and unexplained fatigue. Immediate medical attention is required.
• Congestive heart failure exacerbation - due to fluid retention from pioglitazone; signs include shortness of breath, swelling of ankles, and rapid weight gain.
• Hepatotoxicity - monitor liver enzymes; discontinue if severe elevation occurs.
• Bladder cancer - long-term pioglitazone use has shown a possible association; regular surveillance is advised for high-risk individuals.

Drug Interactions

• CYP2C8 inhibitors (e.g., gemfibrozil, trimethoprim) can increase pioglitazone plasma levels, heightening the risk of edema and heart failure.
• Cimetidine, trimethoprim, and other drugs that reduce renal clearance may raise metformin concentrations and increase lactic acidosis risk.
• Contrast media used in imaging studies can provoke acute kidney injury; temporary discontinuation of metformin is recommended before and after the procedure.
• Insulin or other secretagogues (e.g., sulfonylureas) may increase the risk of hypoglycaemia when combined with Actoplus Met.

Food and Lifestyle Interactions

• Metformin is best absorbed when taken with meals; this reduces gastrointestinal discomfort.
• Alcohol intake should be limited, as it can increase the risk of lactic acidosis.
• Patients should avoid sudden changes in dietary carbohydrate intake without medical guidance, as this may affect glycaemic control.

How to Take Actoplus Met

• Standard dosing: The usual starting dose is one tablet (500 mg/15 mg) taken orally twice daily with meals. The dose may be increased gradually, based on glycaemic response and tolerability, up to the maximum dose approved in Hong Kong.
• Administration: Swallow tablets whole with a full glass of water. Do not crush or chew.
• Missed dose: Take the missed dose at the next scheduled time. Do not double the dose to make up for a missed one.
• Renal adjustment: For patients with moderate renal impairment (eGFR 30-45 mL/min/1.73 m²), consider a reduced dose (e.g., 500 mg/15 mg once daily) and monitor renal function regularly.
• Overdose: Symptoms may include severe gastrointestinal upset, dizziness, rapid breathing, and confusion. Seek emergency medical care; supportive measures and haemodialysis may be required for metformin toxicity.
• Discontinuation: If therapy is to be stopped, tapering is not usually required for metformin, but abrupt cessation of pioglitazone may lead to a rebound increase in blood glucose. Coordinate with a healthcare professional for a safe transition.

Monitoring and Follow-Up

• Glycaemic monitoring: Check fasting plasma glucose and HbA1c every 3 months after initiating or adjusting therapy.
• Renal function: Serum creatinine and eGFR should be measured at baseline and periodically (at least annually) or more often in patients with pre-existing kidney disease.
• Liver enzymes: Baseline ALT/AST levels are recommended; repeat if clinically indicated.
• Weight and edema: Regular assessment of body weight and peripheral oedema helps detect early fluid retention.
• Cardiac status: Patients with a history of heart failure should have their cardiac function evaluated before and during treatment.

Storage and Handling

• Store tablets at room temperature (15-30 °C) in a dry place, protected from moisture and direct sunlight.
• Keep the container tightly closed and out of reach of children.
• Do not use the medication after the expiry date printed on the packaging.

Medication-Specific Glossary

AMPK (AMP-activated protein kinase)

An enzyme that acts as an energy sensor in cells; activation reduces glucose production in the liver and increases glucose uptake in muscle.

PPAR-γ (Peroxisome proliferator-activated receptor-γ)

A nuclear receptor that regulates genes involved in lipid storage and glucose metabolism; targeted by thiazolidinediones to improve insulin sensitivity.

eGFR (estimated glomerular filtration rate)

A calculation that estimates kidney filtering capacity; essential for dosing adjustments of renally cleared drugs such as metformin.

Medical Disclaimer

This article provides educational information about Actoplus Met and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.